Fermion Technology
Fermion is a clinical-stage AI-enabled drug discovery company specializing in small molecule drugs for neurology and autoimmune diseases. They integrate AI, biology, medicinal chemistry, and medicine, utilizing deep learning, reinforcement learning, generative adversarial networks, big data, and knowledge graphs to enhance drug development. Their 'Drug Studio AI Platform' accelerates preclinical research and molecule generation, improving success rates. Fermion focuses on differentiated BIC/FIC products with improved target selectivity and tissue targeting, currently having over ten small molecule drug programs. Founded in 2018 by Dr. Deco Deng, the company has undergone four funding rounds and targets clinical trials within 8-13 months for preclinical stages and 28-30 months for clinical-stage trials.
Fermion Technology
Fermion is a clinical-stage AI-enabled drug discovery company specializing in small molecule drugs for neurology and autoimmune diseases. They integrate AI, biology, medicinal chemistry, and medicine, utilizing deep learning, reinforcement learning, generative adversarial networks, big data, and knowledge graphs to enhance drug development. Their 'Drug Studio AI Platform' accelerates preclinical research and molecule generation, improving success rates. Fermion focuses on differentiated BIC/FIC products with improved target selectivity and tissue targeting, currently having over ten small molecule drug programs. Founded in 2018 by Dr. Deco Deng, the company has undergone four funding rounds and targets clinical trials within 8-13 months for preclinical stages and 28-30 months for clinical-stage trials.